Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design
Pamela A. Trail, Gene M. Dubowchik, Timothy B. Lowinger
Pharmacology & Therapeutics (2017) Vol. 181, pp. 126-142
Closed Access | Times Cited: 112

Showing 1-25 of 112 citing articles:

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Udai Banerji, Carla M.L. van Herpen, Cristina Saura, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 8, pp. 1124-1135
Open Access | Times Cited: 467
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Michael J. Birrer, Kathleen N. Moore, Ilaria Betella, et al.
JNCI Journal of the National Cancer Institute (2019) Vol. 111, Iss. 6, pp. 538-549
Closed Access | Times Cited: 342
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Sònia Pernas, Sara M. Tolaney
Therapeutic Advances in Medical Oncology (2019) Vol. 11
Open Access | Times Cited: 309
Breast Cancer Treatments: Updates and New Challenges
Anna Burguin, Caroline Diorio, Francine Durocher
Journal of Personalized Medicine (2021) Vol. 11, Iss. 8, pp. 808-808
Open Access | Times Cited: 273
Application of magnetic nanoparticles in nucleic acid detection
Congli Tang, Ziyu He, Hongmei Liu, et al.
Journal of Nanobiotechnology (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 200
Cancer immunotherapy beyond immune checkpoint inhibitors
Julian A. Marin‐Acevedo, Aixa Soyano, Bhagirathbhai Dholaria, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 193
Peptide–Drug Conjugates with Different Linkers for Cancer Therapy
Mona Alas, Azam Saghaeidehkordi, Kamaljit Kaur
Journal of Medicinal Chemistry (2020) Vol. 64, Iss. 1, pp. 216-232
Open Access | Times Cited: 162
Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate
Rotimi Sheyi, Beatriz G. de la Torre, Fernando Alberício
Pharmaceutics (2022) Vol. 14, Iss. 2, pp. 396-396
Open Access | Times Cited: 127
Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets
Bonan Chen, Peiyao Yu, Wai Nok Chan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 88
Chemotherapeutic agents for the treatment of metastatic breast cancer: An update
Mariam Abotaleb, Peter Kubatka, Martin Čaprnda, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 101, pp. 458-477
Closed Access | Times Cited: 159
RNA therapy: Are we using the right molecules?
Ai‐Ming Yu, Chao Jian, Allan H. Yu, et al.
Pharmacology & Therapeutics (2018) Vol. 196, pp. 91-104
Open Access | Times Cited: 143
TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2- Metastatic Breast Cancer
Hope S. Rugo, Aditya Bardia, Sara M. Tolaney, et al.
Future Oncology (2020) Vol. 16, Iss. 12, pp. 705-715
Open Access | Times Cited: 106
Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases
Krupa Naran, Trishana Nundalall, Shivan Chetty, et al.
Frontiers in Microbiology (2018) Vol. 9
Open Access | Times Cited: 99
Antibody interface prediction with 3D Zernike descriptors and SVM
Sebastian Daberdaku, Carlo Ferrari
Bioinformatics (2018) Vol. 35, Iss. 11, pp. 1870-1876
Closed Access | Times Cited: 89
Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target
Manisha Taya, Stephen R. Hammes
Steroids (2017) Vol. 133, pp. 102-107
Open Access | Times Cited: 87
Impact of Payload Hydrophobicity on the Stability of Antibody–Drug Conjugates
Jakob W. Buecheler, Matthias Winzer, Jason Tonillo, et al.
Molecular Pharmaceutics (2018) Vol. 15, Iss. 7, pp. 2656-2664
Closed Access | Times Cited: 84
Degrader–Antibody Conjugates: Emerging New Modality
Ki Bum Hong, Hongchan An
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 1, pp. 140-148
Closed Access | Times Cited: 41
Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132
Yezhe Cheng, Xiaoxi Yuan, Qiang Tian, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 38
Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer
Zohreh Najminejad, Fatemeh Dehghani, Yousef Mirzaei, et al.
Molecular Therapy (2023) Vol. 31, Iss. 7, pp. 1874-1903
Open Access | Times Cited: 37
Development of antibody‐drug conjugates in cancer: Overview and prospects
Dan‐Yun Ruan, Hao‐Xiang Wu, Qi Meng, et al.
Cancer Communications (2023) Vol. 44, Iss. 1, pp. 3-22
Open Access | Times Cited: 25
What influences the activity of Degrader−Antibody conjugates (DACs)
Yaolin Guo, Xiaoxue Li, Yang Xie, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116216-116216
Closed Access | Times Cited: 8
Breast Cancer Immunotherapy: An Update
Issam Makhoul, Mohammad Atiq, Ahmed Alwbari, et al.
Breast Cancer Basic and Clinical Research (2018) Vol. 12
Open Access | Times Cited: 63
Interconnection of sulfides and sulfoxides in medicinal chemistry
Abdrrahman Shemsu Surur, Lukas Schulig, Andreas Link
Archiv der Pharmazie (2018), pp. 1800248-1800248
Closed Access | Times Cited: 62
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors
Maria Vittoria Dieci, Federica Miglietta, Gaia Griguolo, et al.
Cancer Treatment Reviews (2020) Vol. 88, pp. 102064-102064
Open Access | Times Cited: 58
Extracellular Matrix: Emerging Roles and Potential Therapeutic Targets for Breast Cancer
Yunchun Zhao, Xiaoling Zheng, Yongquan Zheng, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 45
Page 1 - Next Page

Scroll to top